Drug intelligence / Profile preview

MTA-304

Development stage: Unknown
Lead developer: Mentara Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MTA-304 (formerly EM-221) is a highly selective, second-generation small molecule phosphodiesterase 10A (PDE10A) inhibitor being developed by Mentara Therapeutics. Originally discovered by Mochida Pharmaceutical and previously developed by EuMentis Therapeutics, the compound is designed to target levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. By inhibiting PDE10A, which is highly expressed in the striatum, MTA-304 aims to rebalance striatal signaling pathways overstimulated by levodopa, thereby reducing involuntary movements without diminishing levodopa's therapeutic benefit. MTA-304 has completed three Phase 1 clinical trials demonstrating a favorable safety and tolerability profile, and is planned to enter Phase 2 clinical development in the first half of 2027.

Targets

PDE10A (Phosphodiesterase 10A)

Beyond the preview

Go deeper on MTA-304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTA-304.